WHO launches taskforce to fight counterfeit drugs
WHO will launch a taskforce in late 2006 to fight a thriving multimillion-dollar illegal trade in counterfeit drugs, vaccines and other medical products.
The International Medical Products Anti-Counterfeiting Taskforce (IMPACT) aims to put a stop to the deadly trade in fake drugs, which studies suggest kill thousands of people every year.
“We need to help people become more aware of the growing market in counterfeit medicines and the public health risks associated with this illegal practice,” said Dr Howard Zucker, Assistant Director-General for the Health Technology and Pharmaceuticals cluster of departments at WHO.
The taskforce will encourage the public, distributors, pharmacists and hospital staff to inform the authorities about their suspicions regarding the authenticity of a drug or vaccine. In a parallel move, the taskforce will help governments crack down on corruption in the sections of their police forces and customs authorities charged with enforcing laws against drug counterfeiting. Drug manufacturers will be encouraged to make their products more difficult to fake.
The key members of the taskforce will be national drug regulatory authorities and law enforcement agencies. WHO will also seek the involvement of other international organizations, nongovernmental organizations, pharmaceutical manufacturing and wholesaling industry associations, patient advocacy groups and health-care professionals.
The taskforce will meet for the first time in mid-November in Germany. “We will decide on concrete projects and deliverables. We will decide who will do what and according to what deadlines,” said Dr Valerio Reggi from WHO’s Health Technology and Pharmaceuticals cluster of departments, who will coordinate the taskforce.
The idea of setting up this taskforce was approved at a meeting in Rome in February but it is the latest initiative in a long campaign.
For almost 20 years, WHO has been fighting drug counterfeiting since it became a major threat in the 1980s. “The problem was first noticed by the pharmaceutical industry. They saw that their own products were being copied,” said Reggi, who has worked on drug regulation at WHO since 1989.
An estimated 1 in 4 packets of medicine sold in street markets in developing countries could be fake.
In mainland southeast Asia, artesunate, a vital antimalarial drug, is commonly faked. An international study conducted by Nick White and his colleagues and published in Tropical Medicine and International Health in 2004 found that 53% of artesunate tablet packs sold in the region did not contain artesunate.
Although it is difficult to obtain precise figures, the Food and Drug Administration in the United States of America estimates that worldwide sales of fake drugs exceed US$ 3.5 billion per year, according to a paper published in the journal PLoS Medicine in April 2005. The Center for Medicines in the Public Interest in the USA predicts that counterfeit drug sales could reach US$ 75 billion globally in 2010 if action is not taken to curb the trade.
Counterfeit drugs are found everywhere, but sub-Saharan Africa is particularly affected. “The dismantling of the health-care system in most African countries has created the vacuum into which counterfeiters have been able to slip,” said Reggi.
In Africa, drugs are sold through the informal economy in large open-air markets alongside fruit and vegetables. “People may realize the risk that they take, but there’s no other place to buy drugs,” he said. “Hospitals can’t buy directly from the pharmaceutical companies for many reasons, including cost and the small quantities they need. So they buy drugs from local suppliers who sometimes are not even licensed by the local authorities. Some of these people may be selling fake drugs, either knowingly or unknowingly.”
According to WHO, drugs commonly counterfeited include antibiotics, antimalarials, hormones and steroids. Increasingly, anticancer and antiviral drugs are also faked.
Counterfeiters take inert ingredients such as chalk, and even dangerous chemicals, package them convincingly and sell them to consumers. Such drugs may have no therapeutic effect and can be toxic.
In common with illegal narcotics, fake drugs are trafficked across borders, hidden in items such as teddy bears, or labelled as animal feed. Having escaped detection by customs authorities, the drugs are repackaged in the destination country.
Many studies have documented the impact that counterfeit drugs can have on patients’ health, as well as the way they undermine health systems. Reggi cited the case of a counterfeit iron preparation that has killed pregnant women in Argentina in the last two years. Hundreds of children in Bangladesh suffered kidney failure and many died due to a fake paracetamol syrup diluted with diethylene glycol, according to a study published in the BMJ in 1995.
“The taskforce will coordinate all the organizations involved in combating the manufacture and trade of counterfeit medicines,” said Reggi.
After assessing current national laws on drug counterfeiting, and advising governments on how they might be tightened, the taskforce will attack the corruption that stops the law from being enforced, said Reggi. “We want to explain to corrupt officers that they should not accept bribes because the fake drugs they let through could end up poisoning their own families,” he said. Closer cooperation between police, customs services and health-care providers is also required.
Enforcement officers would like to be able to identify fake drugs on the spot. But sometimes it is impossible to do so without laboratory analysis. “We could make packaging resistant to forgery by using the security devices we find on modern banknotes,” said Reggi. Drugs also need to be readily traceable from the point of manufacture to the point of sale.
“We are working with government agencies and manufacturers to create a database of products,” Reggi said. “Each packet of medicine will have a unique number that could be tracked with widely available and relatively inexpensive technology. This would make it possible to check whether a medicine is genuine at any point in the distribution pipeline.”
Reggi hopes that the taskforce will encourage consumers and health-care providers to report anything suspicious. “We will follow up reports so that people who tell us about suspected counterfeit drug transactions receive feedback and are motivated to report again in the future.”
William Burns, Geneva